Company / FCF Margin
Corcept Therapeutics Incorporated FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
18.6%
FY2025
5-year range
18.6% / 45.8%
FY2021-FY2025
Trend
-35.9%
vs FY2024
Sector context
#35 of 135
Health Care
What the data says
At 18.6%, Corcept Therapeutics Incorporated's fcf margin ranks #35 of 135 in the Health Care sector. FCF Margin has fluctuated over the past 10 years, ranging from -103.8% in FY2016 to 45.8% in FY2021.
Based on SEC 10-K filings.
18.6% in FY2025 with a 5-year CAGR of -24.0%.
Declined from 26.2% to 18.6% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -11.2pp
- 5-Year Change
- -24.0pp
- 10-Year Change
- -
Sector benchmark
#35 of 135 in Health CareTop 26% of 135This company 18.6% Sector average -680.1%
▼
+102.7% above sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 35.9% year-over-year.
- Currently 698.7pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2021.
- Lowest fcf margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 18.6% | -35.9% |
| FY2024 | 29.0% | +10.8% |
| FY2023 | 26.2% | -12.1% |
| FY2022 | 29.8% | -34.8% |
| FY2021 | 45.8% | +7.4% |
| FY2020 | 42.6% | +12.0% |
| FY2019 | 38.0% | +69.8% |
| FY2018 | 22.4% | -41.1% |
| FY2017 | 38.0% | +136.6% |
| FY2016 | -103.8% | -1776.3% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026